These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38795025)

  • 21. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 2023 Latin America report of the
    Hartinger SM; Palmeiro-Silva YK; Llerena-Cayo C; Blanco-Villafuerte L; Escobar LE; Diaz A; Sarmiento JH; Lescano AG; Melo O; Rojas-Rueda D; Takahashi B; Callaghan M; Chesini F; Dasgupta S; Posse CG; Gouveia N; Martins de Carvalho A; Miranda-Chacón Z; Mohajeri N; Pantoja C; Robinson EJZ; Salas MF; Santiago R; Sauma E; Santos-Vega M; Scamman D; Sergeeva M; Souza de Camargo T; Sorensen C; Umaña JD; Yglesias-González M; Walawender M; Buss D; Romanello M
    Lancet Reg Health Am; 2024 May; 33():100746. PubMed ID: 38800647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
    Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
    Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
    Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of Cell-Based Vaccine Manufacturing through Process Intensification.
    Whitford W; SourabiÈ AM; Varshney DB
    PDA J Pharm Sci Technol; 2022; 76(2):151-162. PubMed ID: 34282035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
    Braimoh T; Burrone E; Gore C; Vijayaraghavan P
    Global Health; 2024 Jul; 20(1):52. PubMed ID: 38956614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustainable vaccine manufacturing in low- and middle-Income countries.
    Hayman B; Kumar Suri R; Downham M
    Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries.
    Pidiyar V; Kumraj G; Ahmed K; Ahmed S; Shah S; Majumder P; Verma B; Pathak S; Mukherjee S
    Vaccine; 2022 Aug; 40(36):5302-5312. PubMed ID: 35914959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Industry 4.0 Technologies for the Manufacturing and Distribution of COVID-19 Vaccines.
    Sarfraz A; Sarfraz Z; Sarfraz M; Abdul Razzack A; Bano S; Singh Makkar S; Thevuthasan S; Paul T; Khawar Sana M; Azeem N; Felix M; Cherrez-Ojeda I
    J Prim Care Community Health; 2022; 13():21501319211068638. PubMed ID: 34984932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Cernuschi T; Malvolti S; Hall S; Debruyne L; Bak Pedersen H; Rees H; Cooke E
    Vaccine; 2024 Apr; 42 Suppl 1(Suppl 1):S64-S72. PubMed ID: 38103962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between bisphosphonate use and COVID-19 related outcomes.
    Thompson J; Wang Y; Dreischulte T; Barreiro O; Gonzalez RJ; Hanč P; Matysiak C; Neely HR; Rottenkolber M; Haskell T; Endres S; von Andrian UH
    Elife; 2023 Aug; 12():. PubMed ID: 37534876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
    Joe CCD; Jiang J; Linke T; Li Y; Fedosyuk S; Gupta G; Berg A; Segireddy RR; Mainwaring D; Joshi A; Cashen P; Rees B; Chopra N; Nestola P; Humphreys J; Davies S; Smith N; Bruce S; Verbart D; Bormans D; Knevelman C; Woodyer M; Davies L; Cooper L; Kapanidou M; Bleckwenn N; Pappas D; Lambe T; Smith DC; Green CM; Venkat R; Ritchie AJ; Gilbert SC; Turner R; Douglas AD
    Biotechnol Bioeng; 2022 Jan; 119(1):48-58. PubMed ID: 34585736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.